- Home
- GRF vs RADX Comparison
GRF vs RADX Comparison
Compare GRF & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRF
- RADX
- Stock Information
- Founded
- GRF 1989
- RADX 2021
- Country
- GRF United States
- RADX Australia
- Employees
- GRF N/A
- RADX N/A
- Industry
- GRF Finance/Investors Services
- RADX
- Sector
- GRF Finance
- RADX
- Exchange
- GRF Nasdaq
- RADX NYSE
- Market Cap
- GRF 38.9M
- RADX 32.5M
- IPO Year
- GRF N/A
- RADX N/A
- Fundamental
- Price
- GRF $9.77
- RADX $4.70
- Analyst Decision
- GRF
- RADX Strong Buy
- Analyst Count
- GRF 0
- RADX 2
- Target Price
- GRF N/A
- RADX $13.50
- AVG Volume (30 Days)
- GRF 3.0K
- RADX 21.1K
- Earning Date
- GRF 01-01-0001
- RADX 02-26-2025
- Dividend Yield
- GRF 3.70%
- RADX N/A
- EPS Growth
- GRF N/A
- RADX N/A
- EPS
- GRF 1.16
- RADX N/A
- Revenue
- GRF N/A
- RADX $204,609.00
- Revenue This Year
- GRF N/A
- RADX N/A
- Revenue Next Year
- GRF N/A
- RADX N/A
- P/E Ratio
- GRF $8.15
- RADX N/A
- Revenue Growth
- GRF N/A
- RADX N/A
- 52 Week Low
- GRF $7.93
- RADX $3.50
- 52 Week High
- GRF $10.19
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- GRF 49.55
- RADX N/A
- Support Level
- GRF $9.76
- RADX N/A
- Resistance Level
- GRF $9.82
- RADX N/A
- Average True Range (ATR)
- GRF 0.04
- RADX 0.00
- MACD
- GRF -0.01
- RADX 0.00
- Stochastic Oscillator
- GRF 42.50
- RADX 0.00
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.